bdp 12 has been researched along with olanzapine in 2 studies
| Studies (bdp 12) | Trials (bdp 12) | Recent Studies (post-2010) (bdp 12) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
|---|---|---|---|---|---|
| 62 | 7 | 14 | 6,339 | 1,340 | 2,383 |
| Protein | Taxonomy | bdp 12 (IC50) | olanzapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Didriksen, M; Kreilgaard, M; Olsen, CK | 1 |
| Freudenreich, O; Goff, DC; Green, MF; Johnson, SA; Lamberti, JS; Leon, AC; Manschreck, T; Miller, AL; Patel, J | 1 |
1 trial(s) available for bdp 12 and olanzapine
| Article | Year |
|---|---|
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dioxoles; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pilot Projects; Piperidines; Psychiatric Status Rating Scales; Psychomotor Performance; Risperidone; Sample Size; Schizophrenia; Schizophrenic Psychology | 2008 |
1 other study(ies) available for bdp 12 and olanzapine
| Article | Year |
|---|---|
Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Clozapine; Conditioning, Psychological; Dioxoles; Drug Synergism; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperidines; Pyrimidines; Rats; Rats, Wistar; Receptors, AMPA; Risperidone; Serine; Stereoisomerism | 2006 |